We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Molecular imaging of IDH-mutant gliomas in the new era of IDH inhibitors: preparing for future challenges.
- Authors
Ninatti, Gaia; Moresco, Rosa Maria; Sollini, Martina
- Abstract
The article discusses the recent advancements in the treatment of isocitrate dehydrogenase (IDH) mutant gliomas, a type of brain tumor. The phase 3 INDIGO trial presented in June 2023 showed that vorasidenib, a second-generation oral inhibitor of mutant IDH1/2 enzymes, significantly improved progression-free survival in patients with residual or recurrent grade 2 IDH-mutant gliomas. However, the trial was limited to a specific population and setting, and further studies are needed to validate and generalize the positive outcomes. The article also highlights the need for standardized criteria for tumor grading and the potential of molecular imaging to predict response to IDH-mutant inhibitors. The development of PET radiopharmaceuticals targeting IDH mutations is desirable for accurate detection and monitoring of the mutant IDH1/2 enzymes. Overall, the article emphasizes the importance of keeping up with the advancements in the treatment of IDH-mutant gliomas and the challenges faced by the nuclear medicine and molecular imaging community.
- Subjects
GLIOMAS; BIOMARKERS; YOUNG adults
- Publication
European Journal of Nuclear Medicine & Molecular Imaging, 2024, Vol 51, Issue 5, p1421
- ISSN
1619-7070
- Publication type
Article
- DOI
10.1007/s00259-024-06591-3